Scaling Multimodal AI and Lab-in-the-Loop for Breakthrough R&D

Kate Sasser, PhD, Chief Scientific Officer at Tempus, and Neil Bence, PhD, of Bristol Myers Squibb, discuss how AI and RWD are shaping the future of oncology drug development in this presentation from the AACR Annual Meeting 2026.

May 28, 2026
Life Sciences
Video
Smiling blonde woman with shoulder-length hair wearing a professional dark jacket.Kate Sasser, PhDChief Scientific Officer, Tempus
Black and white headshot of a smiling man with glasses and a suit jacket.Neil Bence, PhDSenior Vice President, Protein Homeostasis Thematic Research Center, Bristol Myers Squibb

Related content

Simple white graphic of a single sheet of paper or document, slightly angled.Article
Person works on computer with abstract digital code and data patterns overlayed.

Bridging the gap: How Target Trial Emulation transforms real-world data into credible evidence

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract digital background with glowing white lines and a fading dotted pattern.

Q&A: Predicting response and resistance in ADCs with AI and multimodal data

2026-08-20
Life Sciences
Simple white graphic of a single sheet of paper or document, slightly angled.Article
Abstract background with light grey gradient, digital dots, and subtle wave patterns.

Researchers across pharma and academia are reducing oncology drug timelines with Tempus Lens

2026-08-12
Life Sciences